Literature DB >> 11952160

Molecular basis of 2',3'-dideoxycytidine-induced drug resistance in human cells.

Annamaria Innoceta1, Luca Galluzzi, Annamaria Ruzzo, Francesca Andreoni, Laura Chiarantini, Mauro Magnani.   

Abstract

Human monoblastoid cells (U937) grown in the presence of therapeutically relevant dideoxycytidine concentrations (0.1 microM) become resistant to the drug thanks to an altered deoxycytidine kinase. In this paper we show that deoxycytidine kinase mRNA is significantly reduced in drug-resistant U937 cells (U937-R) although the deoxycytidine kinase promoter is normal. Anumber of nucleotide deletions, insertions and substitutions was found in the coding region of deoxycytidine kinase gene. Several identified mutations result in truncated forms of the enzyme or in the introduction of stop codons: in one case a complete lack of exon 4 was found. Thus, the deoxycytidine kinase gene accumulates mutations at a very high rate, as already reported for other cytidine analogues (i.e. Ara C) suggesting that the design of new antiviral or anticancer drugs of the cytidine family should take into account the potential development of cell resistance as a critical factor in drug failure.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11952160     DOI: 10.1023/a:1014441209108

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  8 in total

Review 1.  Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection.

Authors:  J C Adkins; D H Peters; D Faulds
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

2.  Cell cycle regulation of deoxycytidine kinase. Evidence for post-transcriptional control.

Authors:  M Hengstschläger; C Denk; E Wawra
Journal:  FEBS Lett       Date:  1993-04-26       Impact factor: 4.124

3.  High incidence of alternatively spliced forms of deoxycytidine kinase in patients with resistant acute myeloid leukemia.

Authors:  M J Veuger; M W Honders; J E Landegent; R Willemze; R M Barge
Journal:  Blood       Date:  2000-08-15       Impact factor: 22.113

4.  Characterization of the deoxycytidine kinase promoter in human lymphoblast cell lines.

Authors:  E H Chen; E E Johnson; S M Vetter; B S Mitchell
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

Review 5.  New targets for pyrimidine antimetabolites for the treatment of solid tumours. 2: Deoxycytidine kinase.

Authors:  V W Ruiz van Haperen; G J Peters
Journal:  Pharm World Sci       Date:  1994-04-15

6.  The role of cytoplasmic deoxycytidine kinase in the mitochondrial effects of the anti-human immunodeficiency virus compound, 2',3'-dideoxycytidine.

Authors:  C H Chen; Y C Cheng
Journal:  J Biol Chem       Date:  1992-02-15       Impact factor: 5.157

7.  2',3'-Dideoxycytidine induced drug resistance in human cells.

Authors:  M Magnani; G Gazzanelli; G Brandi; A Casabianca; A Fraternale; L Chiarantini; L Rossi
Journal:  Life Sci       Date:  1995       Impact factor: 5.037

8.  2',3'-Dideoxycytidine metabolism in a new drug-resistant cell line.

Authors:  M Magnani; G Brandi; A Casabianca; A Fraternale; G F Schiavano; L Rossi; L Chiarantini
Journal:  Biochem J       Date:  1995-11-15       Impact factor: 3.857

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.